Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076695 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ryo Inoue und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 2, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Intractable Diseases Research Foundation, Japan Intractable Diseases (Nanbyo) Research Foundation 2021.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis is a progressive and fatal disease with a poor prognosis. Matrix metalloproteinase-2 is involved in the pathogenesis of organ fibrosis. The role of matrix metalloproteinase-2 in lung fibrosis is unclear. This study evaluated whether overexpression of matrix metalloproteinase-2 affects the development of pulmonary fibrosis. Lung fibrosis was induced by bleomycin in wild-type mice and transgenic mice overexpressing human matrix metalloproteinase-2. Mice expressing human matrix metalloproteinase-2 showed significantly decreased infiltration of inflammatory cells and inflammatory and fibrotic cytokines in the lungs compared to wild-type mice after induction of lung injury and fibrosis with bleomycin. The computed tomography score, Ashcroft score of fibrosis, and lung collagen deposition were significantly reduced in human matrix metalloproteinase transgenic mice compared to wild-type mice. The expression of anti-apoptotic genes was significantly increased, while caspase-3 activity was significantly reduced in the lungs of matrix metalloproteinase-2 transgenic mice compared to wild-type mice. Active matrix metalloproteinase-2 significantly decreased bleomycin-induced apoptosis in alveolar epithelial cells. Matrix metalloproteinase-2 appears to protect against pulmonary fibrosis by inhibiting apoptosis of lung epithelial cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
- Central Institute for Experimental Animals, Kawasaki 210-0821, Japan.
- Department of Diabetes, Metabolism and Endocrinology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
- Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
ORCID-Profile: Corina N D'Alessandro-Gabazza, Esteban C Gabazza
Förderung
- Japan Society for the Promotion of Science
- Japan Intractable Diseases Research Foundation
- Japan Intractable Diseases (Nanbyo) Research Foundation 2021
Zitieren
APA
Inoue, R., Yasuma, T., Fridman D'Alessandro, V., Toda, M., Ito, T., Tomaru, A., D'Alessandro-Gabazza, C. N., Tsuruga, T., Okano, T., Takeshita, A., Nishihama, K., Fujimoto, H., Kobayashi, T., & Gabazza, E. C. (2023). Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076695
Vancouver
Inoue R, Yasuma T, Fridman D'Alessandro V, Toda M, Ito T, Tomaru A, et al. Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076695
BibTeX
@article{Inoue2023,
author = {Inoue, Ryo and Yasuma, Taro and Fridman D'Alessandro, Valeria and Toda, Masaaki and Ito, Toshiyuki and Tomaru, Atsushi and D'Alessandro-Gabazza, Corina N and Tsuruga, Tatsuki and Okano, Tomohito and Takeshita, Atsuro and Nishihama, Kota and Fujimoto, Hajime and Kobayashi, Tetsu and Gabazza, Esteban C},
title = {Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076695}
}
EUVIMED